ArticleTrials2026
Inhaling penehyclidine to prevent perioperative respiratory adverse events in children at risk undergoing sevoflurane anesthesia (PEPSI trial): study protocol for a double-blind, randomized, placebo-controlled trial.
Article in Trials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06624696 (Inhaling Penehyclidine to Prevent Perioperative Respiratory Adverse Events in Children at Risk Undergoing Sevoflurane Anesthesia), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Inhaling Penehyclidine to Prevent Perioperative Respiratory Adverse Events in Children at Risk Undergoing Sevoflurane Anesthesia: a Double-blind, Randomized, Placebo-controlled Trial
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPerioperative respiratory adverse events (PRAEs) remain a challenge for pediatric anesthesia, inhalation of penehyclidine has been showed to reduce postoperative pulmonary complications and enhance the recovery in high-risk surgical adults. Thus, prophylactic penehyclidine inhalation might show promising benefits against PRAEs in children with high risk factors.
aimsTo clarify the effectiveness of inhaling penehyclidine in reducing PRAEs in pediatric patients at risk scheduled for elective surgery following sevoflurane anesthesia with LMA.
methodsThis is a prospective, multicenter, randomized, double-blind, parallel-group, placebo-controlled trial. Two hundred and four children, aged 3 to 7 years, undergoing elective minor ophthalmic surgery, who are at high risk of PRAEs, will be randomized in a ratio of 1:1 to receive either inhaling penehyclidine hydrochloride (PHC, a dose of 0.05 mg/kg, diluted and mixed with normal saline to a total volume of 5 ml) or identical volumes and colour of normal saline within 30 minutes prior to surgery. The primary outcome is the incidence of PRAEs. Secondary outcomes include the airway hyperreactivity (AHR) score, and the severity of laryngospasm and bronchospasm if occurs. Moreover, ease of laryngeal mask airway (LMA) insertion, episode and degree of salivation during removal of LMA, anesthesia-related recovery time, postoperative pain score, incidence of emergence agitation (EA), hemodynamic parameters, other postoperative adverse events related to the study drug within the first 24 postoperative hours, and the development of respiratory infections within 7 days after surgery will be also collected. DISCUSSION: The results of this study will provide valuable insights into the potential role of inhaling PHC in reducing PRAEs in a high-risk pediatric cohort during sevofurane anesthesia with LMA, thereby promoting clinical practice.
trial registrationClinicalTrials.gov (NCT06624696). Registered on 30 September 2024. https://clinicaltrials.gov/study/NCT06624696 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.